Left ventricular hypertrophy is associated with arterial stiffness and vascular calcification in hemodialysis

Kosaku Nitta1, Takashi Akiba, Keiko Uchida

  • 1Department of Medicine, Kidney Center, Tokyo Women's Medical University, Tokyo, Japan. nitta@kc.twmu.ac.jp

Insights

Vascular calcification is the primary driver of left ventricular hypertrophy (LVH) in hemodialysis patients, linked to increased arterial stiffness and hypertension. Understanding these factors is crucial for managing cardiac abnormalities in end-stage renal disease.

Area of Science:

  • Nephrology
  • Cardiology
  • Vascular Medicine

Background:

  • Left ventricular hypertrophy (LVH) is a common cardiac complication in end-stage renal disease (ESRD) patients.
  • Arterial stiffness and vascular calcification are increasingly recognized in ESRD, but their direct link to LVH requires further elucidation.

Purpose of the Study:

  • To investigate the relationship between LVH and arterial stiffness, aortic calcification, and clinical parameters in hemodialysis patients.
  • To determine the contribution of arterial stiffness and calcification to LVH in this population.

Main Methods:

  • Studied 49 hemodialysis patients.
  • Measured arterial stiffness using pulse wave velocity (PWV).
  • Quantified aortic calcification using the aortic calcification index (ACI) via CT scan.
  • Assessed left ventricular mass index (LVMI) using echocardiography.

Main Results:

  • LVMI positively correlated with PWV (r=0.439), systolic blood pressure (r=0.421), and ACI (r=0.467).
  • Stepwise regression identified PWV, systolic blood pressure, and ACI as independent predictors of LVH.
  • Vascular calcification emerged as the most significant contributor to LVH development.

Conclusions:

  • LVH in hemodialysis patients is associated with hypertension, arterial stiffness, and vascular calcification.
  • Vascular calcification significantly contributes to LVH by altering pulsatile dynamics and increasing left ventricular load.
  • Targeting vascular calcification may be key in managing LVH in ESRD.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...